Authors:
Ganly, I
Kirn, D
Eckhardt, SG
Rodriguez, GI
Soutar, DS
Otto, R
Robertson, AG
Park, O
Gulley, ML
Heise, C
VonHoff, DD
Kaye, SB
Citation: I. Ganly et al., A phase I study of Onyx-015, an ELB-attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (vol 6, pg 798, 2000), CLIN CANC R, 7(3), 2001, pp. 754-754
Authors:
Ganly, I
Kim, YT
Hann, B
Balmain, A
Brown, R
Citation: I. Ganly et al., Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis, GENE THER, 8(5), 2001, pp. 369-375
Authors:
Nemunaitis, J
Khuri, F
Ganly, I
Arseneau, J
Posner, M
Vokes, E
Kuhn, J
McCarty, T
Landers, S
Blackburn, A
Romel, L
Randlev, B
Kaye, S
Kirn, D
Citation: J. Nemunaitis et al., Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer, J CL ONCOL, 19(2), 2001, pp. 289-298
Authors:
Khuri, FR
Nemunaitis, J
Ganly, I
Arseneau, J
Tannock, IF
Romel, L
Gore, M
Ironside, J
MacDougall, RH
Heise, C
Randlev, B
Gillenwater, AM
Bruso, P
Kaye, SB
Hong, WK
Kirn, DH
Citation: Fr. Khuri et al., A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, NAT MED, 6(8), 2000, pp. 879-885
Authors:
Ganly, I
Kirn, D
Eckhardt, SG
Rodriguez, GI
Soutar, DS
Otto, R
Robertson, AG
Park, O
Gulley, ML
Heise, C
VonHoff, DD
Kaye, SB
Citation: I. Ganly et al., A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intramorally to patients with recurrent head and neck cancer (vol 6, pg 798, 2000), CLIN CANC R, 6(9), 2000, pp. 3797-3797
Citation: I. Ganly, A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. (vol 6, pg 798, 2000), CLIN CANC R, 6(5), 2000, pp. 2120-2120
Authors:
Ganly, I
Kirn, D
Eckhardt, SG
Rodriguez, GI
Soutar, DS
Otto, R
Robertson, AG
Park, O
Gulley, ML
Heise, C
Von Hoff, DD
Kaye, SB
Citation: I. Ganly et al., A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer, CLIN CANC R, 6(3), 2000, pp. 798-806
Authors:
Heise, C
Ganly, I
Kim, YT
Sampson-Johannes, A
Brown, R
Kirn, D
Citation: C. Heise et al., Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status, GENE THER, 7(22), 2000, pp. 1925-1929
Citation: I. Ganly et Sb. Kaye, Recurrent squamous-cell carcinoma of the head and neck: Overview of current therapy and future prospects, ANN ONCOL, 11(1), 2000, pp. 11-16
Authors:
Nemunaitis, J
Ganly, I
Khuri, F
Arseneau, J
Kuhn, J
McCarty, T
Landers, S
Maples, P
Romel, L
Randlev, B
Reid, T
Kaye, S
Kirn, D
Citation: J. Nemunaitis et al., Selective replication and oncolysis in p53 mutant tumors with ONYX-015, anE1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial, CANCER RES, 60(22), 2000, pp. 6359-6366
Citation: I. Ganly et al., p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy, BR J CANC, 82(2), 2000, pp. 392-398